Generic Name: exemestane

Pronunciation: N/A

Abbreviation: N/A

Other Market Name: N/A

Drug Class: Hormone Therapy Medications

Company: Pfizer

Approval Status: Approved

Generic Version Available: Yes

Experimental Code: N/A

Drug Indication

Aromasin is an aromatase inhibitor approved for adjuvant (post-surgery) treatment of estrogen receptor-positive (ER+) early breast cancer and treatment of ER+ advanced breast cancer in postmenopausal women who previously used tamoxifen.

General Info

The female hormone estrogen stimulates the growth of hormone receptor-positive breast cancer. Aromatase inhibitors block an enzyme that converts other hormones, known as androgens, into estrogen. They do not stop the ovaries from producing estrogen, so premenopausal women should only use them with other drugs that suppress ovarian function.

Studies show that aromatase inhibitors like Aromasin work better than tamoxifen for reducing the risk of recurrence after initial treatment of early breast cancer with surgery, radiation or chemotherapy. Aromasin was first approved in 1999.


Dosing Info:

Aromasin is taken as a tablet once daily after a meal.

Side Effects

Common side effects include hot flashes, muscle and joint pain, fatigue, headache, insomnia and vaginal dryness. Potential serious side effects include cardiovascular problems and bone loss (osteoporosis). Aromasin should not be used during pregnancy.

For More Info:

Patient Assistance Program Info:

Last Reviewed: December 6, 2018